carvedilol has been researched along with Cardiomegaly in 17 studies
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was aimed to investigate the possible inhibitory effects of aliskiren (ALS) and/or carvedilol (CAV) on CaMKIIδ isoforms expression in experimental cardiac hypertrophy." | 7.83 | Effect of aliskiren and carvedilol on expression of Ca(2+)/calmodulin-dependent protein kinase II δ-subunit isoforms in cardiac hypertrophy rat model. ( Abdel Baky, NA; Al-Mohanna, F; Bin-Dayel, AF; Fadda, LM; Mohammad, RA, 2016) |
| "A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure." | 7.74 | Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008) |
| "Genes encoding proteins in the cardiac hypertrophy and protein ubiquitination pathways were downregulated in the RV by carvedilol, while genes encoding proteins in the mitochondrial dysfunction pathway were upregulated by carvedilol." | 5.39 | Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. ( Bogaard, HJ; Drake, JI; Dumur, CI; Fawcett, P; Gomez-Arroyo, J; Kraskauskas, D; Natarajan, R; Voelkel, NF, 2013) |
| "This study was aimed to investigate the possible inhibitory effects of aliskiren (ALS) and/or carvedilol (CAV) on CaMKIIδ isoforms expression in experimental cardiac hypertrophy." | 3.83 | Effect of aliskiren and carvedilol on expression of Ca(2+)/calmodulin-dependent protein kinase II δ-subunit isoforms in cardiac hypertrophy rat model. ( Abdel Baky, NA; Al-Mohanna, F; Bin-Dayel, AF; Fadda, LM; Mohammad, RA, 2016) |
| "A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure." | 3.74 | Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008) |
| "Histological studies have provided evidence that carvedilol can prevent cardiac hypertrophy in spontaneously hypertensive-stroke prone rats (SP) fed a high-fat and -salt diet." | 3.74 | Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction. ( Barone, FC; Brooks, DP; Coatney, RW; Nelson, AH; Ohlstein, EH; Willette, RN, 2007) |
| "To demonstrate the alterations of Protein Kinase C epsilon (PKC epsilon) and components of its signaling complexes after treatment with fosinopril and carvedilol and analyze potential molecular mechanisms of the two drugs for cardiac hypertrophy and heart failure." | 3.73 | Fosinopril and carvedilol reverse hypertrophy and change the levels of protein kinase C epsilon and components of its signaling complex. ( Gao, J; He, H; Ma, L; Wang, P; Wang, W; Wu, H; Zhang, H, 2006) |
| "7 years), with previously untreated essential hypertension and echocardiographically proven left-ventricular hypertrophy, received metoprolol 200 mg daily over a period of 12." | 3.67 | [Regression of myocardial hypertrophy in hypertensives on chronic beta-receptor block]. ( Behr, M; Franz, IW; Ketelhut, R; Wiewel, D, 1986) |
| "Carvedilol was adiministered for 4 weeks starting at week 13." | 1.56 | Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling. ( Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF, 2020) |
| "Genes encoding proteins in the cardiac hypertrophy and protein ubiquitination pathways were downregulated in the RV by carvedilol, while genes encoding proteins in the mitochondrial dysfunction pathway were upregulated by carvedilol." | 1.39 | Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. ( Bogaard, HJ; Drake, JI; Dumur, CI; Fawcett, P; Gomez-Arroyo, J; Kraskauskas, D; Natarajan, R; Voelkel, NF, 2013) |
| "Carvedilol-treated SHR had significantly reduced systolic blood pressures and heart rates throughout the duration of the experiment, and had significantly reduced ventricle/body weights by approximately 9." | 1.29 | Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats. ( Arleth, A; Barone, F; Camden, A; McCartney, L; Ohlstein, EH; Sung, CP; Vickery, L, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, WS | 1 |
| Ibrahim, IAAE | 1 |
| Mahmoud, MF | 1 |
| Mahmoud, AAA | 1 |
| Kazmirczak, F | 1 |
| Martin, CM | 1 |
| Shenoy, C | 1 |
| Mohamed, RMSM | 1 |
| Elshazly, SM | 1 |
| Nafea, OE | 1 |
| Abd El Motteleb, DM | 1 |
| Drake, JI | 1 |
| Gomez-Arroyo, J | 1 |
| Dumur, CI | 1 |
| Kraskauskas, D | 1 |
| Natarajan, R | 1 |
| Bogaard, HJ | 1 |
| Fawcett, P | 1 |
| Voelkel, NF | 1 |
| Rana, S | 1 |
| Datta, K | 1 |
| Reddy, TL | 1 |
| Chatterjee, E | 1 |
| Sen, P | 1 |
| Pal-Bhadra, M | 1 |
| Bhadra, U | 1 |
| Pramanik, A | 1 |
| Pramanik, P | 1 |
| Chawla-Sarkar, M | 1 |
| Sarkar, S | 1 |
| Bin-Dayel, AF | 1 |
| Abdel Baky, NA | 1 |
| Fadda, LM | 1 |
| Mohammad, RA | 1 |
| Al-Mohanna, F | 1 |
| Wang, K | 1 |
| Lu, D | 1 |
| Zhang, B | 1 |
| Wang, S | 1 |
| Liu, Q | 1 |
| Zhang, Q | 1 |
| Geng, J | 1 |
| Shan, Q | 1 |
| Hanada, K | 1 |
| Asari, K | 1 |
| Saito, M | 1 |
| Kawana, J | 1 |
| Mita, M | 1 |
| Ogata, H | 1 |
| Elnakish, MT | 1 |
| Hassona, MD | 1 |
| Alhaj, MA | 1 |
| Moldovan, L | 1 |
| Janssen, PM | 1 |
| Khan, M | 1 |
| Hassanain, HH | 1 |
| Zhang, YJ | 1 |
| Xiang, MX | 1 |
| San, J | 1 |
| Cheng, G | 1 |
| Wang, SS | 1 |
| He, H | 1 |
| Wang, W | 1 |
| Zhang, H | 1 |
| Ma, L | 1 |
| Wu, H | 1 |
| Wang, P | 1 |
| Gao, J | 1 |
| Barone, FC | 1 |
| Willette, RN | 1 |
| Nelson, AH | 1 |
| Ohlstein, EH | 2 |
| Brooks, DP | 1 |
| Coatney, RW | 1 |
| Vickery, L | 1 |
| Arleth, A | 1 |
| Barone, F | 1 |
| Sung, CP | 1 |
| Camden, A | 1 |
| McCartney, L | 1 |
| Sack, MN | 1 |
| Harrington, LS | 1 |
| Jonassen, AK | 1 |
| Mjøs, OD | 1 |
| Yellon, DM | 1 |
| Eichstaedt, H | 2 |
| Danne, O | 1 |
| Schroeder, RJ | 2 |
| Kreuz, D | 1 |
| Auffermann, W | 1 |
| Richter, W | 1 |
| Franz, IW | 1 |
| Wiewel, D | 1 |
| Behr, M | 1 |
| Ketelhut, R | 1 |
1 trial available for carvedilol and Cardiomegaly
| Article | Year |
|---|---|
Left ventricular hypertrophy regression during antihypertensive treatment.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; Carbazoles; Cardiac Volume; Ca | 1992 |
16 other studies available for carvedilol and Cardiomegaly
| Article | Year |
|---|---|
Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling.
Topics: Animals; beta-Arrestin 2; Cardiomegaly; Carvedilol; Cytokines; Diet, High-Fat; Dietary Sugars; Disea | 2020 |
Left Ventricular Noncompaction and Cardiogenic Shock.
Topics: Cardiomegaly; Carvedilol; Coronary Angiography; Dyspnea; Echocardiography; Female; Glycogen Storage | 2020 |
Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4.
Topics: Animals; Apoptosis; Atenolol; beta-Arrestin 2; Blood Pressure; Cardio-Renal Syndrome; Cardiomegaly; | 2021 |
Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension.
Topics: Animals; Carbazoles; Cardiomegaly; Carvedilol; Cluster Analysis; Gene Expression Profiling; Gene Exp | 2013 |
A spatio-temporal cardiomyocyte targeted vector system for efficient delivery of therapeutic payloads to regress cardiac hypertrophy abating bystander effect.
Topics: Animals; Bystander Effect; Carbazoles; Cardiomegaly; Cardiotonic Agents; Carvedilol; Cells, Cultured | 2015 |
Effect of aliskiren and carvedilol on expression of Ca(2+)/calmodulin-dependent protein kinase II δ-subunit isoforms in cardiac hypertrophy rat model.
Topics: Amides; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Carbazoles; Cardiomegaly; Carve | 2016 |
Renal Denervation Attenuates Multi-Organ Fibrosis and Improves Vascular Remodeling in Rats with Transverse Aortic Constriction Induced Cardiomyopathy.
Topics: Alanine Transaminase; Angiotensin II; Animals; Aorta; Blood Pressure; Carbazoles; Cardiomegaly; Card | 2016 |
Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
Topics: Adenylyl Cyclases; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressur | 2008 |
Rac-induced left ventricular dilation in thyroxin-treated ZmRacD transgenic mice: role of cardiomyocyte apoptosis and myocardial fibrosis.
Topics: Animals; Apoptosis; Blotting, Western; Carbazoles; Cardiomegaly; Cardiomyopathies; Carvedilol; Echoc | 2012 |
Effect of matrine and carvedilol on collagen and MMPs activity of hypertrophy myocardium induced by pressure overload.
Topics: Alkaloids; Animals; Carbazoles; Cardiomegaly; Carvedilol; Cells, Cultured; Collagen; Endomyocardial | 2006 |
Fosinopril and carvedilol reverse hypertrophy and change the levels of protein kinase C epsilon and components of its signaling complex.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2006 |
Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Antioxidants; Carbazoles; Cardiomegaly; | 2007 |
Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Aorta; Blood Vessels; Carbazoles; Cardiomega | 1994 |
Coordinate regulation of metabolic enzyme encoding genes during cardiac development and following carvedilol therapy in spontaneously hypertensive rats.
Topics: Acyl-CoA Dehydrogenase; Animals; Antihypertensive Agents; Carbazoles; Cardiomegaly; Carvedilol; Coen | 2000 |
Regression of left ventricular hypertrophy.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Carbazoles; Cardiomegaly; Carvedilol; Echocardiogr | 1992 |
[Regression of myocardial hypertrophy in hypertensives on chronic beta-receptor block].
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Cardiomegaly; Carvedilol; Chronic Di | 1986 |